Press Releases

PALO ALTO, Calif., July 6 /PRNewswire/ -- Coapt Systems, Inc. (www.coaptsystems.com) announced the launch of Hydrelle(TM) a new, FDA-approved hyaluronic acid based dermal filler for the treatment of facial wrinkles, such as nasolabial folds, also called "smile lines." Hydrelle is the first FDA-approved hyaluronic acid filler formulated with an anesthetic (lidocaine) for greater patient comfort. Proven safe and effective, Hydrelle is also a financially attractive alternative to traditional fillers such as Juvederm(R) by Allergan Medical, and Restylane(R) by Medicis Pharmaceutical.

Hydrelle has been specifically formulated to deliver rapid results comparable to other hyaluronic acid fillers; and the lidocaine anesthetic is integrated, providing a more comfortable injection experience for patients. Hydrelle represents an attractive value for patients seeking a safe and cost-effective filler option, since patients only require approximately 50% of typical injection volumes, thus requiring fewer syringes to fully correct facial wrinkles. Hydrelle also represents a significant opportunity for aesthetic professionals to expand their respective practices by offering patients an advanced, long-lasting dermal filler with an affordable price, particularly during volatile economic times.

Hydrelle is indicated for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds. In a randomized, controlled pivotal U.S. study of 208 patients, Hydrelle was proven safe and effective. In a multi-center, international study, Hydrelle demonstrated patient and physician satisfaction, and filler effectiveness for up to one year.

Laureen DeBuono, President and CEO for Coapt Systems stated, "Coapt Systems has established an excellent reputation as a provider of superior, bioabsorbable suspension devices for face lift procedures within the aesthetic marketplace. Now we have a perfect opportunity to compliment our product portfolio with the Hydrelle dermal filler product line." "Hydrelle represents an important clinical and business distribution milestone between Coapt Systems and the world-class hyaluronic acid product developer and manufacturer, Anika Therapeutics (Nasdaq: ANIK)," said DeBuono.

"I look forward to using more Hydrelle and to continuing to offer it to my patients because I have experienced excellent results," said Michael C. Pickart, M.D., F.A.C.S. "The wrinkle correction is very good compared to competitive products currently on the market, and patients have found Hydrelle to be more comfortable during injection, with less pain. In particular, Hydrelle is definitely my preferred filler of choice for the oral commissures, since they are so hard to numb with dental blocks and topical creams."

Coapt Systems Executive Vice President, Global Marketing and Sales, David Barella stated, "The Coapt Systems sales and marketing team is delighted to introduce Hydrelle to the facial aesthetic community throughout the U.S. I believe that a long-lasting, more comfortable, and cost-effective dermal filler represents a valuable advantage to the millions of women and men that seek to improve their facial appearance every year." Additionally, Barella said, "Physicians will also enjoy the convenient, ready-to-use benefits that Hydrelle with lidocaine offers, without costly and labor intensive pre-injection mixing."

To order Hydrelle, please contact Coapt Systems at 800.963.7670, or visit the worldwide web at www.coaptsystems.com. Hydrelle is available to qualified physicians, or properly licensed practitioners only.

About Hydrelle:

Hydrelle is the first FDA-approved injectable dermal filler to combine hyaluronic acid and lidocaine, a local anesthetic that improves patient comfort, and provides physicians with a new alternative for their aesthetic practice. Designed, developed and manufactured by Anika Therapeutics, Hydrelle is formulated for durability based on its proprietary cross-linking technology and the highest concentration of hyaluronic acid. Hydrelle is exclusively distributed within the U.S. by Coapt Systems.

Hydrelle is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds (such as nasolabial folds). In clinical studies, adverse events were usually mild to moderate in nature and generally resolved within seven days. The most common side effects were injection site reactions of swelling, redness, bumps, bruising and tenderness. Hydrelle should not be used by patients with severe allergies. For complete patient safety information, please consult the Hydrelle Instructions for Use.

About Coapt Systems, Inc.:

Coapt Systems develops and markets unique facial rejuvenation products that help produce beautifully natural, long-lasting results for forehead, brow, cheek, and neck lifts. Endotine(R) and Ultratine(TM) are clinically-proven products that provide face lift patients with minimally invasive treatment and rapid recovery. NovielleTM biocompatible hydrogel injectable fillers can provide immediate voice restoration for patients suffering from vocal fold insufficiency. Coapt Systems is venture-backed and headquartered in Palo Alto, California. For more information, please visit www.coaptsystems.com.

About Anika Therapeutics, Inc.:

Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products include ORTHOVISC(R), a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; HYVISC(R), a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; a family of aesthetic dermatology products for facial wrinkles and scar remediation; AMVISC(R), AMVISC(R) Plus, STAARVISC(TM)-II and Shellgel(TM) injectable viscoelastic HA products for ophthalmic surgery; INCERT(R), an HA-based anti-adhesive for surgical applications; ORTHOVISC(R) mini a treatment for osteoarthritis targeting small joints and available in Europe; MONOVISC(TM) a single-injection osteoarthritis product based on Anika's proprietary cross-linking technology and also available in Europe and Turkey; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.

SOURCE Coapt Systems

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/c25743/european_point_of) has announced the addition of Frost & Sullivan's new report "European Point of Care (POC) Infectious Disease Market" to their offering.

This research service gives a detailed analysis of the European point of care (POC) infectious disease market from 2008-2015.

Multiple Benefits Support Widening Adoption of POCT

Recent discoveries and innovations in the realm of molecular diagnostics hold the exciting promise of revolutionising the healthcare arena. "In particular, the evolution of POC testing is expected to have a significant impact on patient care management," notes the analyst of this research. "Additionally, public awareness initiatives and governmental campaigns across Europe are facilitating the uptake of new technologies and highlighting the value of POC molecular diagnostics in the improvement of medical care, reducing overall healthcare costs." One of the drivers associated with the growth of POC testing is the need for clinicians to quickly test results in settings where patient treatment decisions benefit from immediate diagnostic findings such as hospital emergency rooms and physician offices. "The market for POC diagnostic tests is growing rapidly," adds the analyst of this research. "Public health policy makers, insurers and governments are becoming more aware of the need to test for certain infectious diseases." Healthcare authorities such as the FDA, Centre for Disease Control (CDC) and WHO have recognised that certain rapid POC products are not only easier to use, reliable, sensitive and specific, but that they also can be more cost-effective than traditional diagnostic tests performed in the central laboratory.

Personnel Training Critical to Ensure Optimal Use of POCT

The primary concern articulated by most of the healthcare practitioners is the importance of ensuring the accuracy and reliability of POC test machines. In order to ensure accuracy, quality control is seen as important, including the training of personnel who routinely use the POC tests. The issue of cost is at the core of the POC tests and will ultimately dictate decisions regarding the implementation of the technology. The cost associated with staff performing extra duties could be a potential barrier; ensuring POC test quality is a resource-intensive endeavour that involves co-ordinating a variety of devices, locations and staff. The successful implementation and management of POC programmes in a hospital depends on the formation of a standing committee. This committee must be empowered by every level of administration to review all POC testing requests, to select instrumentation to be evaluated and to coordinate the oversight of existing and new POC testing programmes, all within the hospital budget.

"For POC devices, the principal technology challenges will continue to be in test chemistry," comments the analyst of the research. "This core science must facilitate laboratory quality test results while requiring minimal training for users as well as little or no calibration and maintenance." Today, user training becomes all the more important in order to meet the standards of laboratory testing. Hospitals should organise regular training programmes in collaboration with diagnostic device manufacturers to train staff that use the POC instrument regularly. At the same time, the successful establishment of a market for a new test would have marketing demands that are too high and timelines that are too long. Hence, the ideal option for diagnostic companies would be to partner with pharmaceutical firms and focus on those tests that have a clear link to specific therapies, in addition to having an immediate or prospective clinical potential.

Key Topics Covered:

1 Executive Summary

2 Glossary Of Terms And Exchange Rates

3 Industry Challenges

4 European Poc Infectious Disease Market

5 Market Engineering Strategic Recommendations

6 Database Of Key Industry Participants

7 Decision Support Databases

For more information visit http://www.researchandmarkets.com/research/c25743/european_point_of

    Source: Research and Markets Ltd.

MIAMI, FL -- (MARKET WIRE) -- 07/06/09 -- Xynergy Holdings, Inc (PINKSHEETS: XYNH) is pleased to announce that it has acquired ICCA, an emerging global brokerage and consulting firm doing business in Central and South America, and currently brokering a 16.2 Billion Dollar Timber and Lumber deal in Nicaragua.

In an effort to expand its scope of business, and build shareholder equity, Xynergy Holdings has been looking toward establishing strategic alliances with companies that are focused on establishing global commerce. As previously stated, Xynergy's CEO, J. Carlos Ley will continue to focus on current R&D projects, such as the Hydro X Assist(TM) Technology, while also taking the company in a new direction; Xynergy's acquisition of ICCA provides the company with such an opportunity.

"This deal marks a significant shift by Xynergy toward building an international presence," says CEO J. Carlos Ley. "This deal in particular, wherein we can leverage our interests in alternative energy against traditional business transactions like the 16 billion dollar wood extraction and brokerage opportunity in Nicaragua, is exactly how we intend on establishing our footprint in global business." Continues Ley, "We see a lot more than just a commission, we see a business going forward once the wood is extracted and sold."

ICCA is a company focused on Global Commerce. They have established brokerage contracts for the exclusive representation and sale of exotic Tropical Hardwoods from Central America into the USA, and Asia with two different entities. It is important to note that these hardwoods were part of the devastation caused by Hurricane Felix in 2007, and special permits and exceptions have been made in order to salvage the large quantity and variety of wood species devastated by the storm. It is estimated that there is approximately $16.2 Billion worth of wood that requires extraction from the forests.

ICCA plans on promoting the sale of the hardwoods to various global markets, including the USA. Much of this wood can be used for high end furniture manufacturing, as well as for construction of high end homes. ICCA and Xynergy will look for manufacturers, and contractors to partner with as vendors and grow this aspect of the business to bring revenue into the company. Additionally ICCA also has ties with Spain, and has plans to import / export consumer retail products for distribution.

About Xynergy Holdings, Inc.

Xynergy Holdings, Inc. is committed to meeting the world's growing energy needs while also promoting environmentally conscious business practices and sustainability. Their focus is on promoting global commerce within the realm of a global economy.

Safe Harbor Disclosure:

This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Contact:
Xynergy Corporation
Nicky Coachman-Robinson
305-573-0821

LONDON--(BUSINESS WIRE)-- Leading UK registrar of domain names and web hosting, www.LCN.com has announced last week that it has extended its current domain registration discounted prices indefinitely. The price reduction applies to all domain registrations and renewals, resulting in savings of between 20 - 48 per cent for new and existing customers.

Mark Boost, Managing Director, LCN.com, said: "Our decision to lower domain registration and renewal prices comes at a time when website owners are looking to protect their brand identity while saving costs during a difficult economic climate."

A record number of cybersquatting cases were recorded in 2008. The recent high profile cybersquatting case of "Britain's Got Talent" star Susan Boyle highlighted the importance of registering multiple domain extensions to protect brand identity. However, the additional costs associated with this approach can sometimes seem prohibitively expensive.

Mark Boost continued: "When cybersquatters pick up unregistered variations of a companys web address businesses are exposed to both dangerous and costly implications. LCN.com's price reduction allows new and existing customers to protect their brand by registering multiple domain extensions at a greatly reduced cost.

"We see this price drop as a way of thanking our existing customers for their continued support and loyalty. New customers can now register their domain names at extremely competitive prices and take advantage of the benefits that all LCN.com customers receive every day."

The price reduction will be applied to all extensions available for registration through LCN.com, including the most popular .com, .net, .org, .tel top level domain extensions.

LCN.com also offers further savings on multiple year domain registrations and renewals for customers who secure their domain name for an extended period.

For more information, and to register domain names with LCN.com visit: http://www.lcn.com/domain_names

Follow @LCN_com on Twitter for the latest domain name and web hosting promotions.

About LCN.com

LCN.com has been providing world class web hosting since 2000 and have grown to become the UKs largest organically grown web hosting company with over 40,000 hosting customers and over 350,000 domain names registered since its launch in 2000. For more information, visit www.LCN.com

    Source: LCN.com

COCONUT CREEK, Fla., July 6 /PRNewswire/ -- e-Telmed, Inc., (www.etelmed.com) a leader in the telemedicine industry that uses a state-of-the-art comprehensive telemedicine solutions to connect physicians with patients, has selected TransMedia Group as their public relations agency of record. Telemedicine is generally described as the use of communication equipment to link healthcare practitioners and patients in different locations. Unlike other Telemedicine companies, e-Telmed maintains HIPAA compliance, is completely confidential, and provides a one-stop, fully-integrated telemedicine solution for healthcare providers and patients.

e-Telmed's built-in EMR (Electronic Medical Record) / PHR (Personal Health Record) software allows physicians to view and modify patient medical records securely over the internet. In conjunction with the EMR, e-Telmed's PHR system allows patients to view their medical records at any given time or place.

The benefits of e-Telmed are many and include increased cost efficiency, reduced transportation expenses, improved patient access to specialists, improved quality of care and better communication among providers. e-Telmed connects the physician to patients who live nearby or across the country and provides a great way for patients who travel domestically and internationally to stay in touch with their physicians.

Telemedicine is already in place throughout Canada and Europe, and as the U.S. government is mandating that doctors and hospitals upgrade their charts to an electronic format, e-Telmed is poised to be the go-to Telemedicine company with a proven track record. e-Telmed is a leader in this industry because they provide thousands of telemedicine encounters to its rapidly growing nationwide patient network.

Recently, e-Telmed was chosen to provide Telemedicine services to a federally funded tribal organization that serves native Alaskans in remote villages throughout the state.

According to e-Telmed CEO Lancelot James, "We chose TransMedia Group to assist us in spreading the word to physicians and consumers who would benefit from Telemedicine. Because e-Telmed is an innovator who has produced the first comprehensive telemedicine solution, we're certain that TransMedia Group's experience and excellent track record in the medical field will be instrumental to our rapid growth and growing reputation."

About TransMedia Group

TransMedia Group, headquartered in Boca Raton, FL, is an award-winning PR and marketing firm that has served clients worldwide since 1981. For more information visit www.transmediagroup.com

    Contact: Kim Morgan
    561-750-9800 x233
    kmorgan@transmediagroup.com

SOURCE TransMedia Group